Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
FL-301
i
Other names:
FL-301, NBL-015, FL301, FL 301, NBL015, NBL 015
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
CSPC Pharma, Leap Therap
Drug class:
CLDN18.2 inhibitor
Related drugs:
‹
zolbetuximab-clzb (11)
ZL-1211 (4)
TJ-CD4B (4)
AZD5863 (3)
AB011 (2)
ASP2138 (2)
TST001 (2)
MIL93 (1)
Q-1802 (1)
ASKB589 (0)
BNT141 (0)
DR30303 (0)
IBI-389 (0)
IBI360 (0)
LB4330 (0)
LM-102 (0)
PM1032 (0)
PM3023 (0)
PT886 (0)
QLS31905 (0)
SG1906 (0)
TAC101-Claudin18.2 (0)
AMG 910 (0)
zolbetuximab-clzb (11)
ZL-1211 (4)
TJ-CD4B (4)
AZD5863 (3)
AB011 (2)
ASP2138 (2)
TST001 (2)
MIL93 (1)
Q-1802 (1)
ASKB589 (0)
BNT141 (0)
DR30303 (0)
IBI-389 (0)
IBI360 (0)
LB4330 (0)
LM-102 (0)
PM1032 (0)
PM3023 (0)
PT886 (0)
QLS31905 (0)
SG1906 (0)
TAC101-Claudin18.2 (0)
AMG 910 (0)
›
Associations
News
Trials
Filter by
Latest
almost3years
NBL-015-CSP-001: Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=410, Not yet recruiting, NovaRock Biotherapeutics, Ltd
almost 3 years ago
Clinical • New P1 trial
|
CLDN18 (Claudin 18)
|
FL-301
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login